KYORIN Pharmaceutical (4569) Q1 2025 earnings summary

Executive summary

• Net sales for Q1 FY2024 rose 2.0% year-over-year to ¥28,419 million, with operating profit up 32.0% to ¥1,150 million and ordinary profit up 32.0% to ¥1,417 million.

• Profit attributable to owners of parent increased 12.4% year-over-year to ¥885 million.

• Comprehensive income for Q1 FY2024 was ¥1,173 million, down 7.2% year-over-year.

Financial highlights

• Earnings per share (basic) for Q1 FY2024 was ¥15.42.

• Total assets as of June 30, 2024, were ¥179,911 million, with net assets at ¥130,047 million and an equity ratio of 72.3%.

• Dividend forecast for FY2025 remains unchanged at ¥52.00 per share (¥20.00 interim, ¥32.00 year-end).

Outlook and guidance

• Full-year FY2025 net sales forecast at ¥123,400 million, up 3.2% year-over-year.

• Operating profit projected at ¥6,500 million (+4.3%), ordinary profit at ¥6,900 million (+1.1%), and profit attributable to owners at ¥5,000 million (-8.7%).

• Full-year EPS forecast at ¥87.03.